A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL

Background In lymphoid malignancies, the introduction of chimeric antigen receptor T (CAR-T) cells and bispecific antibodies (bsAbs) has achieved remarkable clinical success. However, such immunotherapeutic strategies are not yet established for acute myeloid leukemia (AML), the most common form of...

Полное описание

Библиографические подробности

Главные авторы:	Melanie Märklin, Gundram Jung, Jonas S Heitmann, Joseph Kauer, Helmut R Salih, Stefanie Mueller, Bochong Li, Latifa Zekri, Naveen K Mehta, Martin Pfluegler, Kristan Meetze, Isabelle Sindel, Fabian Vogt, Lukas Osburg, Hans-Jörg Bühring, Sebastian Hörner, Patrick A Baeuerle, Jennifer S Michaelson
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMJ Publishing Group 2022-03-01
Серии:	Journal for ImmunoTherapy of Cancer
Online-ссылка:	https://jitc.bmj.com/content/10/3/e003882.full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!